ALL-REZ BFM 2002 is associated with improved outcome as compared to ALL-R3 strategy in children with standard risk isolated cns relapse of acute lymphoblastic leukemia, while maintaining comparable efficacy in patients with bone marrow relapse. results of the multi-national, multi-center Trial IntReALL SR 2010
Authors
von Stackelberg, A.Bourquin, J. P.
Zimmermann, M.
Revesz, T.
Attarbaschi, A.
Ferster, A.
Sramkova, L.
Frandsen, T. L.
Lahteenmaki, P. M.
Elhasid, R.
Toyoda, H.
Hoogerbrugge, P. M.
Johannsdottir, I. M.
Duarte, X.
Bonney, D.
Saha, Vaskar
Steffen, I. G.
Lissat, A.
Chen-Santel, C.
Eckert, C.
Baruchel, A.
Petit, A.
Cave, H.
Rizzari, C.
Cazzaniga, G.
Vinti, L.
Rohrlich, P.
Locatelli, F.
Affiliation
Pediatric Oncology and Hematology, Charité, Med. Univ., Berlin, Berlin, GermanyIssue Date
2022
Metadata
Show full item recordCitation
von Stackelberg A, Bourquin JP, Zimmermann M, Revesz T, Attarbaschi A, Ferster A, et al. ALL-REZ BFM 2002 Is Associated with Improved Outcome as Compared to ALL-R3 Strategy in Children with Standard Risk Isolated CNS Relapse of Acute Lymphoblastic Leukemia, while Maintaining Comparable Efficacy in Patients with Bone Marrow Relapse. Results of the Multi-National, Multi-Center Trial IntReALL SR 2010. Blood. 2022 Nov;140:3247-9. PubMed PMID: WOS:000893223203127.Journal
BloodDOI
10.1182/blood-2022-166234Additional Links
https://dx.doi.org/10.1182/blood-2022-166234Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1182/blood-2022-166234